Informatics-Driven Efforts for the Diagnosis of Rare Genetic Disorders

BIOINFO 2021 OnBIT Award Lecture

Sungwon Jung, Ph.D

Department of Genome Medicine and Science, Gachon University College of Medicine

Gachon Institute of Genome Medicine and Science, Gachon University Gil Medical Center







What is Rare Genetic Disorder?

Definition

- Diseases caused by genetic abnormalities among diseases in which prevalence (20,000 or diagnosis is difficult (in Korea)
 - Varies by countries

(US: < 200,000, Japan: < 50,000, Eurpoe: Ratio < 1/2,000, etc.)

Characteristics

- Genetic
 - Hereditary: 80%
 - Pediatric: > 50%






- High mortality
 - 35% of deaths within the first year of life
 - 30% die within five years of life



- Diversity: More than 7,000 diseases reported
 - Diversity in phenotypes and genotypes

Affecting 5 ~ 10% of population

Difficulty in diagnosis





- Due to rarity, diversity, genetic natures
- Visits 7 MDs on average until diagnosis
- 5 to 7 years on average until correct diagnosis

Value of diagnosis

- Gives answer to patients with the cause of disease
- Potential chances for treatment
- Genetic counseling to patients and parents
- Leads to new drug R&D
 - Personalized anti-sense oligonucleotide (ASO), etc.
 - Life-long treatment



Diagnosis of Rare Genetic Disorders





Clinical observation of patient's abnormal phenotypes







Previously reported > 6,000 disorders

Phenotypes

Causal genes



Identifying patient's genetic variations



Prioritizing potentially causative pathogenic genetic variants



Final diagnosis of patient




Diagnosis of Rare Genetic Disorders

Step 1: Clinical diagnosis



- Identifying abnormal phenotypes
- (Listing candidate diseases)

Step 2: Identifying rare genetic variants




Identifying genetic variations



Filtering genetic variants with low VAF

Step 3: Prioritizing pathogenic genetic variants





	A	D			G		AJ	AK	AL	AM	AN	AO	
1	Gene.refGer	Chr	Start	End	Ref	Alt	SIFT_score	SIFT_pred	Polyphen2_I	Polyphen2_	Polyphen2_H	Polyphen2_	Н
2	GJB4	chr1	35226964	35226964	G	A	0.06	T	0.993	D	0.706	P	
3	FPGT-TNNI3	chr1	74716436	74716436	C	G	0.01	D	1	D	0.996	D	
4	PPOX	chr1	161138854	161138854	С	G	0.04	D	0.997	D	0.944	D	
5	FCGR2A	chr1	161483723	161483723	G	A	-999		-999		-999		
								_		_		-	

- Prioritization based on diagnosis guidelines (e.g., ACMG)
 - Specific implementation of each guideline step is mandatory
- Computational prediction of pathogenicity is not good enough

Step 4: Final diagnosis





- Comparison with known diseasegene phenotype information
- Largely subjective evaluation on phenotype similarity
- Co-evaluation of phenotype and variant pathogenicity is also subjective in general.



Pathogenic Variant Prioritization

Variant pathogenicity prediction





- Ongoing development of variant pathogenicity prediction software using various characteristics
- NA/AA sequence characteristics o pathogenic variant
- Protein structure and function
- Ensemble integration of multiple prediction tools

(Zhang et al., Genetics in Medicine 2020)




Pathogenic Variant Prioritization: Limitation

Incomplete coverage of genomic variation


- Most clinical applications target specific genomic regions
- Selected disease genes
- Coding regions
- Missing genomic regulations beyond DNA sequence
- Limited utilization of gene expression & protein information
- Missing tissue-specificity
- Most clinical applications rely on germline DNA from blood cells

Low accuracy of pathogenic variant prioritization

Patients usually have multiple likely-pathogenic variants.



* Evaluation using the data of 108 patients with confirmed diagnosis (unpublished)








Advances in Pathogenic Variant Identification: Extending Coverage

Whole-genome sequencing

- Identifying non-coding/structural variants
- Rapid WGS such as STAT-Seq
- 30~40X WGS variant analysis within 50 hrs
- Custom HW such as Illumina DRAGEN
- 30X WGS analysis within 25 mins










Phenotype Matching


Curation of disease gene-phenotypes

The Human Gene Mutation Database



Online Mendelian Inheritance in Man

Standardization of phenotypes



- Human Phenotype Ontology (by Monarch initiative)
- Consortium of EMBL-EBI, Jackson lab, etc.
- Tree-structured definition of phenotype ontology
- More than 13,000 phenotype terms
- More than 156,000 annotations to hereditary disease



Phenotype Matching: Challenge

308350 DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1; DEE1 INHERITANCE - X-linked recessive HEAD & NECK Head - Decreased head circumference RESPIRATORY - Dyspnea ABDOMEN Gastrointestina - Dysphagia NEUROLOGIC Central Nervous System - Seizures, intractable - Myoclonic seizures - Hypsarrhythmia - Arrest of psychomotor development after seizure onset - Mental retardation - Dystonia - Status dystonicus - Choreoathetosis - Ouadriplegic dyskinesia - Axial hypotonia - Hypertonia - Hyperreflexia - Spasticity - MRI shows T2-weighted signals in the basal ganglia MISCELLANEOUS - Onset of seizures in first months of life (usually 4 to 7 months) - Dyskinesias occur in a subset of patients later than seizures (6 to 12 months) - Males are most severely affected, but females can also be affected - Caused by mutation in the X-linked aristaless-related homeobox gene (ARX, 300382.0001) Contributors: Cassandra L. Kniffin - revised: 12/26/2007 Creation Date: John F. Jackson: 6/15/1995 Edit History: ckniffin: 04/01/2010

ICD+ # 300055 INTELLECTUAL DEVELOPMENTAL DISORDER, X-LINKED, SYNDROMIC 13: MRXS13 INHERITANCE - X-linked recessive HEAD & NECK - Microcephaly 👤 - Micrognathia 👤 - Facial hypotonia Large ears Mouth - High-arched palate - Sialorrhea Teeth - Bruxism - Short neck 👤 GENITOURINARY External Genitalia (Male) - Macroorchidism (described in 1 family) SKELETAL - Pes cavus 👤 MUSCLE, SOFT TISSUES - Distal atrophy of the legs NEUROLOGIC Central Nervous System - Mental retardation - Delayed development - Delayed speech - Spasticity - Tremor - Ataxia - Parkinsonism - Shuffling gait - Spastic gait

- Hyperreflexia

- Increased tone

- A patient does not show all the previously reported phenotypes.
- Multiple diseases can show similar phenotypes.
- Matching known disease information with patient's phenotypes often requires expert clinician's involvement.



OMIM [2]

OMIM 🔼

OMIM Z


OMIM [7]


10

Advances in Utilizing Phenotype Information: HPO Example

Fine definition of phenotypes

"The Human Phenotype Ontology in 2021" (Kohler et al. NAR 2020)






"Seizure" terms are increased from 68 to 348 by the seizure classification quideline from International League Against Epilepsy (ILAE).

Curating phenotype frequencies


Perrault Syndrome 3 OMIM:614129 Any Perrault syndrome in which the cause of the disease is a mutation in the CLPP gene Vary rare (1 – 4%) Occasional (5 – 29%) Gene Associations Frequent (30 – 79%) nheritance [1 annotation] Very frequent (80 – 99%) Obligate (100%) HP:0000007 Autosomal recessive inheritance Growth [1 annotation] HP:0004322 Short stature Occasional Developmental And Epileptic Encephalopathy 2 OMIM:300672 Any early infantile epileptic encephalopathy in which the cause of the disease is a mutation in the CDKL5 gene. Export Associations Gene Associations Inheritance [1 annotation] X-linked dominant inheritance OMIM [2] PubMed 🖪 HP:0002020 Gastroesophageal reflux 1/5 PubMed 🖪 Constipation 3/5 HP:0002019 Skeletal system [1 annotation] PubMed 🗐




Advances in Utilizing Phenotype Information: Integrated Tools




PhenoVar (BMC Medical Genomics 2014)



* Evaluation using the data of 108 patients with confirmed diagnosis (unpublished)










Application in Clinical Environment

Integration in clinical environment


- Example) GenomeDiver (Pearson et al., Genetics in Medicine 2021)
- 1) Patient's variants and initial phenotyping are put into the system.
- 2) The system generates candidate genes (and diseases) with relevant phenotypes.
- 3) Clinical refines patient's phenotypes.
- 4) The system re-analyzes using the refined phenotypes.
- 5) Feedback to data analysist.






GenomeDiver generates, based on clinician feedback:

- ranked variants
- additional HPO terms
- · potential disease associations











Clinician flags potentially relevant diseases and attaches comments



Application in Clinical Environment: Regulations in Korea

Medical devices guideline (2017)

< 표 1. 의료영상을 이용한 빅데이터 및 인공지능 기술이 적용된 의료기기의 품목 예시 >

번호	품목명(등급)	정 의		
1	의료영상분석장치	의료영상을 획득하여 모의 치료, 모의 시술, 진단에 사용가능		
	소프트웨어(2)	하도록 분석하는 장치에 사용하는 소프트웨어		
2	방사선치료계획	획득된 의료용 영상을 이용하여 방사선 모의 치료 및 모의		
2	소프트웨어(2)	시술에 사용되는 소프트웨어		
	이르어시거초보조	의료영상 내에서 정상과 다른 이상 부위를 검출 한 후 윤곽선,		
3	의료영상검출보조	색상 또는 지시선 등으로 표시하여 의료인의 진단결정을 보조		
	소프트웨어(2)	하는데 사용하는 소프트웨어		
	이글어시되다버포	의료영상을 사용하여 질병의 유무, 질병의 중증도 또는 질병의		
4	의료영상진단보조	상태 등에 대한 가능성 정도를 자동으로 표시하여 의료인의		
	소프트웨어(3)	진단결정을 보조하는데 사용하는 소프트웨어		

< 표 2. 의료영상 이외의 의료정보를 이용한 빅데이터 및 인공지능 기술이 적용된 의료기기의 품목(안) >

번호	품목명(등급)	정 의
		환자의 각종 생체정보(의료영상 제외)를 사용하여 정상과
١,	생체신호검출보조	다른 이상 신호를 검출한 후 알람을 제공하거나 색상
'	소프트웨어(2)	또는 지시선 등으로 표시하여 의료인의 진단결정을 보조
		하는데 사용하는 소프트웨어
		환자의 각종 생체정보(의료영상 제외)를 사용하여 질병의
2	생체신호진단보조	유무, 질병의 중증도 또는 질병의 상태 등을 진단 또는
2	소프트웨어(3)	예측하거나 가능성 정도를 자동으로 표시하여 의료인의
		진단결정을 보조하는데 사용하는 소프트웨어
	인체유래검체	인체 유래 검체를 분석하여 정상과 다른 특이적인 결과를
3	검출보조	제공하여 의료인의 진단결정을 보조하는데 사용하는
	소프트웨어(2)	소프트웨어
	الملاح المال المال	인체 유래 검체를 분석하여 질병의 유무, 질병의 중증도
١,	인체유래검체	또는 질병의 상태 등을 진단 또는 예측하거나 가능성
4	진단보조	정도를 자동으로 표시하여 의료인의 진단결정을 보조
	소프트웨어(3)	하는데 사용하는 소프트웨어

Law on IVD (2020. 5. 1.)

체외진단의료기기법

[시행 2020. 5. 1.] [법률 제16433호, 2019. 4. 30., 제정]

식품의약품안전처(의료기기정책과), 043-719-3755

제1장 총칙

- **제1조(목적)** 이 법은 체외진단의료기기의 제조·수입 등 취급과 관리 및 지원에 필요한 사항을 규정하여 체외진단의료기기의 안전성 확보 및 품질 향상을 도모하고 체외진단의료기기의 국제경쟁력을 강화함으로써 국민보건 향상 및 체외진단의료기기의 발전에 이바지함을 목적으로 한다.
- □ 제2조(정의) 이 법에서 사용하는 용어의 뜻은 다음과 같다.
 - 1. "체외진단의료기기"란 사람이나 동물로부터 유래하는 검체를 체외에서 검사하기 위하여 단독 또는 조합하여 사용되는 시약, 대조 · 보정 물질, 기구 · 기계 · 장치, 소프트웨어 등 <u>의료기기법</u> 제2조제1항에 따른 의료기기로서 다음 각 목의 어느 하나에 해당하는 제품을 말한다.
 - 가. 생리학적 또는 병리학적 상태를 진단할 목적으로 사용되는 제품
 - 나. 질병의 소인(素因)을 판단하거나 질병의 예후를 관찰하기 위한 목적으로 사용되는 제품
 - 다. 선천적인 장애에 대한 정보 제공을 목적으로 사용되는 제품
 - 라. 혈액, 조직 등을 다른 사람에게 수혈하거나 이식하고자 할 때 안전성 및 적합성 판단에 필요한 정보 제공을 목적으로 사용되는 제품
 - 마. 치료 반응 및 치료 결과를 예측하기 위한 목적으로 사용되는 제품
 - 바. 치료 방법을 결정하거나 치료 효과 또는 부작용을 모니터링하기 위한 목적으로 사용되는 제품
 - 2. "검체"라 인체 또는 동물로부터 수집하거나 채취한 조직·세포·혈액·체액·소변·분변 등과 이들로부터 분리된 혈청, 혈장, 염색체, DNA(Deoxyribonucleic acid), RNA(Ribonucleic acid), 단백질 등을 말한다.
 - 3. "임상적 성능시험"이란 체외진단의료기기의 성능을 증명하기 위하여 검체를 분석하여 임상적·생리적·병리학적 상태와 관련된 결과를 확인하는 시험을 말한다.

P01000 체외진단 소프트웨어 IVD software for diagnosis

P01010.01 질환진단검사소프트웨어 [2] IVD software for diagnosis to disease, except cancer, tumor 다수의 임상검사정보만 입력하거나 생체지표를 추가 입력하여 감염진단, 미생물 동정, 특정질환(암 제외)의 진단보조 등 진단정보를 제공하는 소프트웨어




Application in Clinical Environment: Regulations in Korea

Target disease selection

- IVD approval requires clinical performance test.
- Clinical performance test covering all rare genetic disorders – Very difficult

Diagnosis of epilepsy by genetic disorder



GMP Certification

 With a product, product manufacturing system, and quality management system

Clinical performance test

- Typical rare genetic disorder diagnosis software: 2nd grade IVD software
- Requires: Approval of plan for clinical performance test
- Requires: Clinical performance test at MFDSdesignated test sites
- Prospective test can be very difficult for rare genetic disorders. - Retrospective test may be used.
- maybe 1st IVD software for rare genetic disorder?



Summary

- Informatics nature in the diagnosis of rare genetic disorders
 - Requires large patient cohorts for proper data curation
 - Requires various pattern recognitions and information processing
 - Well-designed systems can help clinicians.
- Ongoing changes in laws and regulations
 - For better application of informatics technologies